GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update

Why It Matters

The results show GENFIT’s diversified royalty income and strong cash position, funding a pipeline that could add high‑value liver‑disease therapies and diagnostics to its revenue mix.

Key Takeaways

• Cash €101.1M (~$109M) ensures runway past 2028.
• 2025 revenue €65.4M (~$70.6M) driven by royalties.
• Iqirvo full-year sales $208M, triggered $20M milestone.
• MASH diagnostic reimbursement approved, boosting commercial potential.
• Phase‑2 ACLF trial launches H2 2026, results expected 2027.

Pulse Analysis

GENFIT’s 2025 financials illustrate how royalty‑based models can underpin biotech cash flow. The company’s partnership with Ipsen on Iqirvo®—the first approved therapy for primary biliary cholangitis—delivered $208 million in sales, surpassing expectations and unlocking a $20 million milestone. This success, combined with a €30 million (~$32 million) royalty‑financing tranche, has extended GENFIT’s cash runway well beyond 2028, giving it the flexibility to invest in late‑stage assets without dilutive financing.

Beyond pharmaceuticals, GENFIT is positioning its non‑invasive diagnostic platform for metabolic dysfunction‑associated steatohepatitis (MASH) as a cornerstone of the emerging MASH market. Recent Medicare and Medicaid reimbursement for its NASHnext® test validates the technology’s clinical utility and opens a pathway to larger payer adoption. As the MASH therapeutic landscape expands—forecast to exceed $1 billion in sales—the need for reliable patient‑identification tools grows, positioning GENFIT to capture significant royalty streams and potential licensing fees.

Looking ahead, GENFIT’s pipeline includes several high‑risk, high‑reward programs. Phase 2 initiation for the ACLF candidate NTZ in the second half of 2026, coupled with orphan‑drug designation, could address a critical unmet need and generate future royalties. Simultaneously, the CCA combination therapy GNS561 is advancing toward Phase 2, while the PSC Phase 3 trial with Ipsen could unlock a market comparable to PBC. These developments, underpinned by a solid cash base, suggest that GENFIT is well‑placed to translate scientific advances into commercial value over the next few years.